Davies Rhian Siân, Smith Christian, Edwards Gwenllian, Butler Rachel, Parry Diane, Lester Jason Francis
Velindre Cancer Centre, Cardiff, UK.
Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.
Lung Cancer Int. 2017;2017:9614938. doi: 10.1155/2017/9614938. Epub 2017 Mar 7.
. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of histological diagnosis. . The records of 70 patients with advanced adenocarcinoma of the lung managed through a single multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether this was sent for EGFR testing, and the result. . Seventy patients were identified. In 21/25 (84%) cases, cytological sampling was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing was not carried out in 22/70 (31.4%) patients. There was insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other reasons for not testing included poor patient fitness and problems in the diagnostic pathway. . In this series, cytological tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.
在肺癌分子亚群的识别和理解方面已取得进展，这些亚群由特定的致癌畸变所定义。已确定了一些可采取行动的基因改变，如表皮生长因子受体（EGFR）突变。我们旨在确定患者在组织学诊断时未进行EGFR突变检测的原因。回顾了在单一机构由单一多学科团队管理的70例晚期肺腺癌患者的记录。收集了关于肿瘤样本采集方法的数据，是否送检进行EGFR检测以及检测结果。确定了70例患者。在21/25（84%）的病例中，细胞学采样足以进行EGFR突变分析，相比之下，组织学采样的病例为40/45（89%）。22/70（31.4%）的患者未进行EGFR突变检测。9/22（40.9%）的患者没有足够的肿瘤样本进行EGFR检测。未检测的其他原因包括患者身体状况不佳和诊断流程中的问题。在本系列中，细胞学肿瘤采样并非癌症未能确定EGFR突变状态的主要原因。
